Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for... see more

Recent & Breaking News (NDAQ:CNSP)

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

PR Newswire June 30, 2020

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

GlobeNewswire June 29, 2020

Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020

GlobeNewswire June 23, 2020

CNS To Present at the Life Sciences Investor Forum

PR Newswire June 23, 2020

CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

PR Newswire June 11, 2020

CNS Announces Highlights from Annual Meeting of Shareholders

PR Newswire June 9, 2020

CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

PR Newswire May 28, 2020

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

PR Newswire May 27, 2020

Nasdaq Scheduled Resumption in CNS Pharmaceuticals Inc.

GlobeNewswire May 27, 2020

CNS Provides Update on Development Agreement for WP1122

PR Newswire May 27, 2020

Nasdaq Halts CNS Pharmaceuticals Inc.

GlobeNewswire May 18, 2020

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

PR Newswire May 18, 2020

CNS Provides Additional Comments Regarding Trading Halt

PR Newswire May 11, 2020

Investor Alert: Kaplan Fox Investigates CNS Pharmaceuticals

PR Newswire May 8, 2020

CNS Pharmaceuticals Announces Trading Halt

PR Newswire May 4, 2020

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

GlobeNewswire April 30, 2020

CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial

PR Newswire April 30, 2020

WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin

GlobeNewswire April 24, 2020

CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin

PR Newswire April 23, 2020

CNS Pharmaceuticals to Host Shareholder Webinar Today to Discuss Coronavirus Collaboration, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

PR Newswire April 22, 2020